Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIKIOTCMKTS:ALGXYOTCMKTS:RPBCOTCMKTS:VRACY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIKIAIkido Pharma$5.27+0.4%$5.24$3.31▼$11.48$28.91M0.9379,326 shs72,855 shsALGXYAffinity Energy and Health$0.00$0.00▼$0.26N/A135.11800 shsN/ARPBCRedpoint Bio$0.00+∞$0.00$0.00▼$0.00N/AN/A101,150 shs200,000 shsVRACYViralytics$3.75$0.00$1.50▼$4.10N/AN/A247 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIKIAIkido Pharma0.00%-5.05%+8.66%+45.18%+162.19%ALGXYAffinity Energy and Health0.00%0.00%0.00%0.00%0.00%RPBCRedpoint Bio0.00%0.00%0.00%0.00%0.00%VRACYViralytics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIKIAIkido PharmaN/AN/AN/AN/AN/AN/AN/AN/AALGXYAffinity Energy and HealthN/AN/AN/AN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AN/AN/AN/AVRACYViralyticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIKIAIkido Pharma 0.00N/AN/AN/AALGXYAffinity Energy and Health 0.00N/AN/AN/ARPBCRedpoint Bio 0.00N/AN/AN/AVRACYViralytics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIKIAIkido PharmaN/AN/AN/AN/A$19.27 per shareN/AALGXYAffinity Energy and Health$2.05MN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AN/AVRACYViralyticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIKIAIkido Pharma-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/AALGXYAffinity Energy and Health-$6.08MN/A0.00N/AN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/A0.00∞N/AN/AN/AN/AN/AVRACYViralyticsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIKIAIkido PharmaN/AN/AN/AN/AN/AALGXYAffinity Energy and HealthN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AVRACYViralyticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIKIAIkido PharmaN/A29.5429.54ALGXYAffinity Energy and HealthN/AN/AN/ARPBCRedpoint BioN/AN/AN/AVRACYViralyticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIKIAIkido Pharma10.88%ALGXYAffinity Energy and HealthN/ARPBCRedpoint BioN/AVRACYViralyticsN/AInsider OwnershipCompanyInsider OwnershipAIKIAIkido Pharma8.60%ALGXYAffinity Energy and HealthN/ARPBCRedpoint Bio11.51%VRACYViralyticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIKIAIkido Pharma45.49 million5.01 millionNot OptionableALGXYAffinity Energy and HealthN/AN/AN/ANot OptionableRPBCRedpoint BioN/AN/AN/ANot OptionableVRACYViralyticsN/AN/AN/ANot OptionableVRACY, ALGXY, RPBC, and AIKI HeadlinesRecent News About These CompaniesOncolytics: the dawn of a new era in cancer treatmentOctober 17, 2024 | pharmaphorum.comPViralytics lifted by FDA panel verdict on T-VecSeptember 6, 2024 | pharmaphorum.comPBig pharma could turn to viruses to boost cancer immunotherapiesAugust 16, 2024 | pharmaphorum.comPReflection and refraction of light - CCEAMay 27, 2024 | bbc.co.ukBridgewater founder Ray Dalio warns of danger of US debt to Treasury marketMay 18, 2024 | ft.comViewRay, Inc. (VRAY)April 22, 2024 | finance.yahoo.com50% Off Ray-Ban Promo Codes - MarchMarch 20, 2024 | latimes.comWhat is Billy Ray Cyrus' net worth?March 6, 2024 | celebritynetworth.comCThe best 4K Blu-ray players 2024: Ultra HD marvels chosen by our expertsMarch 3, 2024 | techradar.comTThe Ray D'Arcy ShowFebruary 13, 2024 | rte.ieRDistrict Attorney Once Linked To Jerry Sandusky Investigation Disappears: "It’s Truly Like He Did Vanish Into Thin Air"February 5, 2024 | oxygen.comORay, MI Weather ConditionsFebruary 1, 2024 | wunderground.comWTo Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?January 5, 2024 | ascopubs.orgARay Romano Explains Why an ‘Everybody Loves Raymond’ Reboot Is ‘Out of the Question'December 20, 2023 | mensjournal.comMoncolytic virusDecember 15, 2023 | pharmaphorum.comPRachael Ray Cookware ReviewsDecember 14, 2023 | consumeraffairs.comCRay Anderson out at Arizona State? Good luck to whoever's nextNovember 25, 2023 | azcentral.comALenses and ray diagrams - OCR GatewayNovember 25, 2023 | bbc.co.ukArizona State Athletic Director Ray Anderson resignsNovember 24, 2023 | azcentral.comATop broker names 3 healthcare shares to buyOctober 27, 2023 | fool.com.auMedia Sentiment Over TimeVRACY, ALGXY, RPBC, and AIKI Company DescriptionsAIkido Pharma NASDAQ:AIKI$5.27 +0.02 (+0.38%) As of 07/3/2025AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Affinity Energy and Health OTCMKTS:ALGXYAffinity Energy and Health Limited operates as a plant-based health and wellbeing company in Australia, India, and the United States. It engages in developing technology to produce commercial quantities of algae and medicinal cannabis for supply to algae-based nutraceuticals, animal feed and aquaculture, medicinal cannabis, and biofuels markets. The company offers FeedMe Algae, an algae-based aqua feed; and algae-based biofuels. Affinity Energy and Health Limited was founded in 2007 and is based in Subiaco, Australia.Redpoint Bio OTCMKTS:RPBC$0.0001 +0.00 (+∞) As of 07/23/2019Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.Viralytics OTCMKTS:VRACYViralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia. As of June 20, 2018, Viralytics Limited operates as a subsidiary of Merck Sharp & Dohme (Holdings) Pty Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
